Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2026)

Amneal Pharmaceuticals has reported Receivables - Other for 10 years, with the latest figure at $4.6 million in Q2 2026.

• On a quarterly basis, Receivables - Other fell 71.81% year-over-year to $4.6 million in Q2 2026; TTM through Jun 2026 was $4.6 million, a 71.81% decrease from a year earlier, with the FY2025 full-year figure at $24.2 million, up 441.87% from the prior year.
• Receivables - Other was $4.6 million for Q2 2026 at Amneal Pharmaceuticals, down from $6.2 million in the prior quarter.
• The five-year high for Receivables - Other was $100.0 million in Q2 2022, with the low at $4.5 million in Q4 2024.
• Average Receivables - Other over 5 years is $24.6 million, with a median of $14.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other soared 4184.3% in 2022, then plunged 85.53% in 2023.
• Over 5 years, Receivables - Other stood at $73.0 million in 2022, then slumped by 79.31% to $15.1 million in 2023, then plunged by 70.44% to $4.5 million in 2024, then soared by 441.87% to $24.2 million in 2025, then slumped by 80.98% to $4.6 million in 2026.
• The last three Receivables - Other figures came in at $4.6 million (Q2 2026), $6.2 million (Q1 2026), and $24.2 million (Q4 2025), per Business Quant data.